Pentifylline
Based on 1 Customer Validation
Pentifylline (1-Hexyltheobromine; Hexyltheobromine), PTX (HY-B0715) precursor compound, is a vasodilator. Pentifylline decreases procollagen levels and inhibits collagen production. Pentifylline reduces functional nuclear NF-1 to suppress procollagen gene transcription.
For research use only. We do not sell to patients.
- Purity: 99.23%
- CAS No.: 1028-33-7
- Formula: C13H20N4O2
- Molecular Weight:264.32
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Clinical Compound Library
HY-L026
-
Drug Repurposing Compound Library
HY-L035
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Cytoskeleton Compound Library
HY-L060
-
Coagulation and Anti-coagulation Compound Library
HY-L136
-
Antihypertensive Compound Library
HY-L145
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Biological Activity
Pentifylline (1-100 μg/mL; 48 h) potently inhibits collagen production in normal adult dermal fibroblasts with an ID50 of approximately 10 μg/mL[2].
Pentifylline (100 μg/mL; 48 h) decreases extracellular type I procollagen by 76% and type III procollagen by 97% in normal adult dermal fibroblasts[2].
Pentifylline (100 μg/mL; 48 h) decreases steady-state procollagen α1(I), α2(I), and α1(III) mRNA levels by 95%, 80%, and 98% respectively in normal adult dermal fibroblasts, an effect dependent on new protein synthesis[2].
Pentifylline (100 μg/mL; 48 h) eliminates detectable nuclear NF-1 DNA-binding activity in normal adult dermal fibroblasts, without directly blocking NF-1-DNA interactions[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:normal adult dermal fibroblasts (from facial and mammary skin, third to ninth passages)
-
Concentration:100 μg/mL
-
Incubation Time:48 h
-
Result:Decreased extracellular type I procollagen by 76% and type III procollagen by 97% (assessed by densitometry), reducing both the α1 and α2 chains of type I procollagen.
Chemical Information
-
CAS No. 1028-33-7
-
Appearance Solid
-
Molecular Weight 264.32
-
Formula C13H20N4O2
-
Color White to off-white
-
SMILES
CCCCCCN1C(=O)C2=C(N=CN2C)N(C)C1=O
-
Synonyms
1-Hexyltheobromine; Hexyltheobromine
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 100 mg/mL (378.33 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Aviado D M, et al. Pentoxifylline: a new drug for the treatment of intermittent claudication; mechanism of action, pharmacokinetics, clinical efficacy and adverse effects[J]. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1984, 4(6): 297-306. [Content Brief]
[2]. Duncan MR, et al. Pentoxifylline, pentifylline, and interferons decrease type I and III procollagen mRNA levels in dermal fibroblasts: evidence for mediation by nuclear factor 1 down-regulation. J Invest Dermatol. 1995;104(2):282-286. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.7833 mL | 18.9165 mL | 37.8329 mL | 94.5823 mL |
| 5 mM | 0.7567 mL | 3.7833 mL | 7.5666 mL | 18.9165 mL | |
| 10 mM | 0.3783 mL | 1.8916 mL | 3.7833 mL | 9.4582 mL | |
| 15 mM | 0.2522 mL | 1.2611 mL | 2.5222 mL | 6.3055 mL | |
| 20 mM | 0.1892 mL | 0.9458 mL | 1.8916 mL | 4.7291 mL | |
| 25 mM | 0.1513 mL | 0.7567 mL | 1.5133 mL | 3.7833 mL | |
| 30 mM | 0.1261 mL | 0.6305 mL | 1.2611 mL | 3.1527 mL | |
| 40 mM | 0.0946 mL | 0.4729 mL | 0.9458 mL | 2.3646 mL | |
| 50 mM | 0.0757 mL | 0.3783 mL | 0.7567 mL | 1.8916 mL | |
| 60 mM | 0.0631 mL | 0.3153 mL | 0.6305 mL | 1.5764 mL | |
| 80 mM | 0.0473 mL | 0.2365 mL | 0.4729 mL | 1.1823 mL | |
| 100 mM | 0.0378 mL | 0.1892 mL | 0.3783 mL | 0.9458 mL |
Powered by Bioz